Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.56B
Close$
$3.64
83.7% downside
Current Fair Value
83.7% downsideOvervalued by 83.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.56 Billion |
|---|---|
| Enterprise Value | $3.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.07 |
| Outstanding Shares | 155,521,048 |
Return
| Return on Equity | -22.96% |
|---|---|
| Return on Assets | -9.82% |
| Return on Invested Capital | -10.35% |
Valuation & Multiples
| P/E Ratio | -68.02 |
|---|---|
| PEG | 206.8 |
| Price to Sales | 22.27 |
| Price to Book Ratio | 22.27 |
| Enterprise Value to Revenue | 12.67 |
| Enterprise Value to EBIT | -86.38 |
| Enterprise Value to Net Income | -76 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 1.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$61.03 M
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 15.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.93%▼ 98.23% |
|---|---|
| Total Invested | $30.98M▼ 98.53% |
| Investors Holding | 29▼ 270.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...